Abstract
Since the first report by Wara and Colleagues1 on the immunological reconstitution of a child with Di George syndrome after treatment with thymosin Fr.V, thymic hormone therapy has been attempted in a number of primary immunodeficiency (ID) diseases.2–4 For some of these disorders, such as Di George syndrome and thymic aplasia, this form of treatment may now be considered as the first choice. Preliminary data also suggest its effectiveness in patients with Ataxia-telangiectasia and Wiskott-Aldrich syndrome.3,4
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
D.W. Wara, A.L. Goldstein, N.E. Doyle, and A.L. Ammann, Thymo sin activity in patients with immunodeficiency, N. Engl. J. Med. 292: 70 (1975).
F. Aiuti, P. Ammirati, M. Fiorilli, R. D’Amelio, F. Franchi, M. Calvani, and L. Businco, Immunological and clinical investigation on a bovine thymic extract. II. Therapeutical applications in primary immunodeficiencies, Pediat. Res. 13: 797 (1979).
D.W. Wara, and A.J. Ammann, Thymosin treatment of children with primary immunodeficiency diseases, Transplant. Proc. 10: 203 (1978).
M. Fiorilli, P. Ammirati, M.C. Sirianni, R. D’Amelio, I. Quinti, M.C. Voci, and F. Aiuti, Present knowledge of thymic hormones with particular reference to thymostimulin, in: “Thymus, Thymic Hormones and T Lymphocytes,” F. Aiuti and H. Wigzell, eds., p. 323, Academic Press, London (1980).
T.A. Waldman, S. Broder, R.M. Blaese, Role of suppressor T cells in the pathogenesis of common variable hypogammaglobulinaemia, Lancet ii: 609 (1974).
F.P. Siegal, M. Siegal, and R.A. Good, Role of helper, suppressor and B cell defects in the pathogenesis of hypogammaglobulinaemias, N. Engl. J. Med. 299: 172 (1978).
G. Doria, G. D’Agostaro, D. Frasca, and M. Garavini, Thymic factors enhance T-T cell cooperation in antibody response of ageing, in: “Thymus, Thymic Hormones and T lymphocytes,” F. Aiuti and H. Wigzell,, p. 229, Academic Press, London.
B. Serrou, D Cupissol, J. Caraux, C. Thierry, C. Rosenfeld, and A.L. Goldstein, Ability of thymosin to decrease in vivo and in vitro suppressor cell activity in tumor bearing mice and cancer patients, Rec. Rep. Cancer Res. 75: 110 (1980).
W.H.O., Immunodeficiency. W.H.O. Tech. Rep. Series, No. 630 (1978).
H. Mac Whinney, V.F.D. Gleahill, and S. McCrea, In vitro and in vivo responses to thymosin in severe combined immunodeficiency, Clin. Immunol. Immunopathol. 14: 196 (1979).
M. Fiorilli, M.C. Sirianni, F. Pandolfi, I. Quinti, U. Tosti, F. Aiuti, and G. Goldstein, Improvement of natural killer activity after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency, Clin. Exp. Immunol. 45: 344 (1981).
T.L.K. Low, and A.L. Goldstein, Structure and function of thymosin and other thymic factors, in: “The Year in Hematology,” R. Silber, J. Lobue, and A.S. Grodon, eds., Plenum (1978).
J.F. Bach, One or several thymic hormones? Rec. Res. Cancer Res. 75: 106 (1980).
G. Goldstein, M.P. Scheid, E.A. Boyse, D.H. Schlesinger, and J. Van Wauwe, A synthetic penatapeptide with biological activity characteristic of the thymic hormone thymopoietin, Science 203: 1309 (1979).
G.D. Marshall, G.B. Thurman, T.L.K. Low, and A.L. Goldstein, Thymosin: Basic properties and clinical application in the treatment of immunodeficiency diseases and cancer. Rec. Res. Cancer Res. 75: 101 (1980).
M. Fiorilli, I. Quinti, M.C. Sirianni, F. Pandolfi, L. Businco, and F. Aiuti, Immunological reconstitution of a patient with severe combined immunodeficiency and Zn+ deficiency after the administration of thymopoietin pentapeptide or of exogenous Zn+, Immunol. Clin., in press.
F. Aiuti, L. Businco, P. Rossi, and I. Quinti, Response to thymopoietin pentapeptide in a patient with Di George syndrome, Lancet i: 91 (1980).
H. Verhaegen, W. De Cock, J. De Cree, and G. Goldstein, Restoration of the impaired lymphocyte stimulation in old people by thymopoietin pentapeptide, J. Clin. Lab. Immunol. 6: 103 (1981).
T. Di Perri, F. Laghi-Pasini, and A. Auteri, Immunokinetics of a single dose of thymopoietin pentapeptide, J. Immunopharmacol. 2: 567 (1980).
R.B. Herberman, J.Y. Djeu, H.D. Kay, J.R. Ortaldo, C. Riccardi, G. D. Bonnard, H.T. Holden, R. Fagnani, A. Santoni, and P. Puccetti, Natural killer cells: characteristics and regulation of activity, Immunol. Rev. 44: 43 (1979).
B.L. Reinherz, and S.F. Schlossman, The differentiation and function of human T lymphocytes, Cell 19: 821 (1980).
S. Horowitz, W. Borcherding, A.W. Moorthy, R. Chesny, H. Schulze-Wisserman, and R. Hong, Induction of suppressor T cells in systemic lupus erythematosus by thymosin and cultured thymic epithelium, Science 197: 999 (1977).
D.B. Kaufman, Maturational effects of thymic hormones on human helper and suppressor T cells: effects of FTS (Facteur Thymique Serique) and thymosin, Clin. Immunol. Immunopathol. 39: 722 (1980).
C.Y. Lau, and G. Goldstein, Functional effects of thymopoietin pentapeptide (TP5) on cytotoxic lymphocyte precursor units (CLP-U). I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation, J. Immunol. 124: 1861 (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
Fiorilli, M. (1984). Thymic Hormone Therapy of Primary Immunodeficiency Diseases. In: Fudenberg, H.H., Whitten, H.D., Ambrogi, F. (eds) Immunomodulation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9358-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9358-4_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9360-7
Online ISBN: 978-1-4615-9358-4
eBook Packages: Springer Book Archive